4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

S-4/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

S-4/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

10-Q - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

S-4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

10-K/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- VanderbiltReport.com, a financial news and content platform, reports that Coeptis Therapeutics (NASDAQ:COEP) is pioneering a dual-track model designed to sustain innovation while reducing reliance on dilutive funding. The biotech industry is known for high burn rates and long timelines. Companies often face an impossible choice between continuous capital raises or scaling back scientific ambitions. Coeptis is demonstrating that hybrid business models can provide a sustainable alternative. Revenue and Research Together In Q2 2025, Coeptis generated $200,681 in revenue while advancing its GEAR Cell Therapy Platform for cancer

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd ("Yorkville").   The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company's outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, "The extinguishment of these outstanding debt obligations strengthens the Company's capital structure and positions us well to pursue our long-term goals." Management notes that a streamlined capital struct

WEXFORD, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the Securities and Exchange Commission ("SEC") related to the Company's previously announced and proposed definitive merger agreement (the "Merger") with Z Squared Inc. ("Z Squared"). The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement has not yet become effective, and the information contained therein is subject to change. About Coeptis Therapeutics Hold

WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (NASDAQ:COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences' proprietary Snap-Car NK cell therapy platform in oncology using Monarch's small molecule adaptor technology. This agreement grants SNAP Biosciences access to Monarch's novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform.

NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & Robotics Initiatives as It Awaits Italian Government ‘Golden Power' Approval NUBURU, Inc. (NYSE:BURU), a leader in high-power blue laser technology, announced today that it has filed with the Securities and Exchange Commission a Form S-3 Registration statement for $100 million. This strategic move is designed to provide the company with the necessary capital to facilitate the ongoing acquisition plan and successfully relaunch its Blue Laser technology business unit. As reaffirmed in the latest communications, NUBURU aims at completing the purchase of defense and secur

WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) ("Coeptis" or the "Company"), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious diseases, and Z Squared Inc. ("Z Squared"), a Dogecoin mining company, today announced they have entered into a definitive merger agreement for a business combination that will result in Z Squared becoming a wholly-owned subsidiary of Coeptis. Under the terms of the merger agreement, a wholly-owned subsidiary of Coeptis will merge with and into Z Squared and the holders of the outstanding Z Squared shares will receive equity in

WEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with U.S.-based NexGenAI Solutions Group (https://nexgenai.io) and Indian technology firm Ishvara Tech Consulting LLP. The new facility, operated by Ishvara Tech Consulting LLP, will serve as a collaborative space for the NexGenAI Affiliates Group (https://nexgenaiaffiliates.io) fostering advancements in artificial intelligence (AI), blockchain technologies, digital transformation, and robotic soluti

Shareholder Update: Strengthening Business Lines Through Innovative Applications in Blue Laser Technology, Artificial Intelligence, Robotics, and Fintech Solutions NUBURU, Inc. (NYSE:BURU), a leader in high-power and high-brightness industrial blue laser technology, is excited to provide a comprehensive update to its shareholders regarding its newly formulated business model canvas, which encompasses two synergistic key business lines. Blue Laser Technology & Product Development. NUBURU is revitalizing its blue-laser technology business unit by collaborating closely with the previous management team to develop a new strategic plan aimed specifically at addressing the defense sector's nee

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep r

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network "NexGen" and NUBURU, Inc. "NUBURU" (NYSE:BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS' strategic position in technology and Artificial Intelligence and NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model entering defense

Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat